Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy.

T, Mok; YL, Wu; JS, Lee; CJ, Yu; V, Sriuranpong; J, Sandoval-Tan; G, Ladrera; S, Thongprasert; V, Srimuninnimit; M, Liao; Y, Zhu; C, Zhou; F, Fuerte; B, Margono; W, Wen; J, Tsai; M, Truman; B, Klughammer; DS, Shames; L, Wu

doi:10.1158/1078-0432.ccr-14-2594

Public

Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy.

Shared by NobleBlocks on Mar 31, 2015 • 12:00 AM UTC

Authors:

Mok T

Wu YL

Lee JS

Abstract

Purpose Blood-based circulating-free (cf) tumor DNA may be an alternative to tissue-based EGFR mutation testing in NSCLC. This exploratory analysis compares matched tumor and blood samples from the FASTACT-2 study.Experimental design Patients were randomized to receive six cycles of gemcitabine/plat...

Discussions